Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian Haferkamp

Showing results (101-110 of 149) with videos related to

Pageof 15
Sort By:
European Journal of Cancer (Oxford, England : 1990)|February 26, 2026
Treatment patterns in geriatric patients with melanoma and the effect of age on the efficacy of immunotherapy: Analysis from the real-world multicenter registry ADOREGKonstantinos Lallas, Lena Nanz, Selma Ugurel, et al.
Journal of Medical Internet Research|July 13, 2021
Integrating Patient Data Into Skin Cancer Classification Using Convolutional Neural Networks: Systematic ReviewJulia Höhn, Achim Hekler, Eva Krieghoff-Henning, et al.
European Journal of Cancer (Oxford, England : 1990)|June 28, 2025
Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinomaViola K DeTemple, Martin Kaatz, Eggert Stockfleth, et al.
European Journal of Cancer (Oxford, England : 1990)|May 28, 2023
Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREGAnne Zaremba, Peter Mohr, Ralf Gutzmer, et al.
European Journal of Cancer (Oxford, England : 1990)|June 27, 2017
Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibitionMarkus V Heppt, Lucie Heinzerling, Katharina C Kähler, et al.
Annals of Surgical Oncology|April 7, 2025
An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal MelanomaJonathan S Zager, Marlana Orloff, Pier Francesco Ferrucci, et al.
Journal for Immunotherapy of Cancer|October 23, 2020
Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patientsUlrike Leiter, Carmen Loquai, Lydia Reinhardt, et al.
Frontiers in Immunology|June 25, 2024
Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse eventsElias A T Koch, Anne Petzold, Edgar Dippel, et al.
European Journal of Cancer (Oxford, England : 1990)|April 2, 2022
MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREGSophia Kreft, Valerie Glutsch, Anne Zaremba, et al.
Annals of Surgical Oncology|May 4, 2024
Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 StudyJonathan S Zager, Marlana Orloff, Pier Francesco Ferrucci, et al.
Pageof 15

Showing results (101-110 of 149) with videos related to

Sort By:
Pageof 15
European Journal of Cancer (Oxford, England : 1990)|February 26, 2026
Treatment patterns in geriatric patients with melanoma and the effect of age on the efficacy of immunotherapy: Analysis from the real-world multicenter registry ADOREGKonstantinos Lallas, Lena Nanz, Selma Ugurel, et al.
Journal of Medical Internet Research|July 13, 2021
Integrating Patient Data Into Skin Cancer Classification Using Convolutional Neural Networks: Systematic ReviewJulia Höhn, Achim Hekler, Eva Krieghoff-Henning, et al.
European Journal of Cancer (Oxford, England : 1990)|June 28, 2025
Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinomaViola K DeTemple, Martin Kaatz, Eggert Stockfleth, et al.
European Journal of Cancer (Oxford, England : 1990)|May 28, 2023
Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREGAnne Zaremba, Peter Mohr, Ralf Gutzmer, et al.
European Journal of Cancer (Oxford, England : 1990)|June 27, 2017
Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibitionMarkus V Heppt, Lucie Heinzerling, Katharina C Kähler, et al.
Annals of Surgical Oncology|April 7, 2025
An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal MelanomaJonathan S Zager, Marlana Orloff, Pier Francesco Ferrucci, et al.
Journal for Immunotherapy of Cancer|October 23, 2020
Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patientsUlrike Leiter, Carmen Loquai, Lydia Reinhardt, et al.
Frontiers in Immunology|June 25, 2024
Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse eventsElias A T Koch, Anne Petzold, Edgar Dippel, et al.
European Journal of Cancer (Oxford, England : 1990)|April 2, 2022
MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREGSophia Kreft, Valerie Glutsch, Anne Zaremba, et al.
Annals of Surgical Oncology|May 4, 2024
Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 StudyJonathan S Zager, Marlana Orloff, Pier Francesco Ferrucci, et al.
Pageof 15